Get the Stockscreener App
9.09
0.66%
0.06
After Hours:
8.97
-0.12
-1.32%
Mind Medicine Inc stock is traded at $9.09, with a volume of 1.19M.
It is up +0.66% in the last 24 hours and up +40.06% over the past month.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
See More
Previous Close:
$9.03
Open:
$9.01
24h Volume:
1.19M
Relative Volume:
1.01
Market Cap:
$686.78M
Revenue:
$11.40B
Net Income/Loss:
$-95.73M
P/E Ratio:
-3.7102
EPS:
-2.45
Net Cash Flow:
$-64.37M
1W Performance:
-6.48%
1M Performance:
+40.06%
6M Performance:
+33.87%
1Y Performance:
-1.84%
1-Day Range:
$9.00
$9.40
1-Week Range:
$8.94
$9.8204
52-Week Range:
$4.70
$10.44
Mind Medicine Inc Stock (MNMD) Company Profile
Name
Mind Medicine Inc
Sector
Industry
Phone
212-220-6633
Address
ONE WORLD TRADE CENTER, NEW YORK
Compare MNMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNMD
Mind Medicine Inc
|
9.09 | 682.25M | 11.40B | -95.73M | -64.37M | -2.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Mind Medicine Inc Stock (MNMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Evercore ISI | Outperform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Jul-24-24 | Initiated | ROTH MKM | Buy |
| May-29-24 | Initiated | Robert W. Baird | Outperform |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | Canaccord Genuity | Buy |
| Dec-09-22 | Resumed | ROTH Capital | Buy |
| Nov-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-26-22 | Initiated | Oppenheimer | Outperform |
| Aug-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-04-22 | Initiated | ROTH Capital | Buy |
| Jun-28-21 | Initiated | Maxim Group | Buy |
View All
Mind Medicine Inc Stock (MNMD) Latest News
Mind Medicine (MindMed) Q2 2025 Earnings Call Transcript - MarketBeat
MindMed August 2025 presentation slides: Phase 3 trials advance with $238M cash runway - Investing.com Nigeria
MindMed August 2025 presentation slides: Phase 3 trials advance with $238M cash runway By Investing.com - Investing.com South Africa
MindMed Reports Strong Q2 2025 Financial Results - TipRanks
MindMed Reports Q2 2025 Financial Results and Business Updates - Stock Titan
What are the latest earnings results for Mind Medicine (MindMed) Inc.Entry Signal Forecasts With Low Risk - jammulinksnews.com
What is the risk reward ratio of investing in Mind Medicine (MindMed) Inc. stockEntry Signal Growth Plan That Work - jammulinksnews.com
What are the technical indicators suggesting about Mind Medicine (MindMed) Inc.Chart Pattern Forecasts For Consistent Profits - jammulinksnews.com
Published on: 2025-07-31 05:18:02 - metal.it
What risks could impact Mind Medicine (MindMed) Inc. stock performanceFree Access to Investment Community - beatles.ru
Custom Dashboard Highlights Mind Medicine (MindMed) Inc. Price MomentumConservative Long Term Growth Plans Under Review - metal.it
Mind Medicine MNMD 2025Q2 Earnings Preview Upside Potential on Strong Analyst Ratings - AInvest
Published on: 2025-07-29 03:31:44 - metal.it
Published on: 2025-07-28 17:15:17 - beatles.ru
Why is Mind Medicine (MindMed) Inc. stock attracting strong analyst attentionFinancial News Tracker With High Returns - jammulinksnews.com
What are analysts’ price targets for Mind Medicine (MindMed) Inc. in the next 12 monthsInvest smarter with real-time trading alerts - jammulinksnews.com
How does Mind Medicine (MindMed) Inc. generate profit in a changing economyExpert guidance for superior capital growth - jammulinksnews.com
When is Mind Medicine (MindMed) Inc. stock expected to show significant growthCapitalize on strong market momentum - jammulinksnews.com
How many analysts rate Mind Medicine (MindMed) Inc. as a “Buy”Discover undervalued stocks before they soar - jammulinksnews.com
Is Mind Medicine (MindMed) Inc. a good long term investmentTriple-digit returns - PrintWeekIndia
Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Mind Medicine: Heading In The Right Direction (NASDAQ:MNMD) - Seeking Alpha
MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025 - Business Wire
All You Need to Know About Mind Medicine MindMed (MNMD) Rating Upgrade to Buy - MSN
What analysts say about Mind Medicine (MindMed) Inc. stockExplosive capital appreciation - jammulinksnews.com
Mind Medicine (MindMed) Inc. Stock Analysis and ForecastExplosive capital appreciation - jammulinksnews.com
Mind Medicine (MindMed) Stock (MNMD) Opinions on Psychedelic Therapy Political Momentum - Nasdaq
(MNMD) Trading Signals - news.stocktradersdaily.com
What drives Mind Medicine (MindMed) Inc. stock priceLightning-fast capital gains - jammulinksnews.com
Don't Trip. These Psychedelic Stocks May Have Some Life in Them Yet - US News Money
Mind Medicine Inc Stock (MNMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):